Pilot study of DNA methylation-derived neutrophil-to-lymphocyte ratio and survival in pediatric medulloblastoma

Vidal M. Arroyo, Philip J. Lupo, Michael E. Scheurer, Surya P. Rednam, Jeffrey Murray, M. Fatih Okcu, Murali Chintagumpala, Austin L. Brown

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Introduction: Methylation-derived neutrophil-to-lymphocyte ratio (mdNLR) has been identified as a potential prognostic biomarker of outcomes in various cancers. We evaluated the prognostic value of blood-derived mdNLR within a retrospective cohort of pediatric medulloblastoma patients. Materials and methods: DNA methylation was measured in archival peripheral blood samples collected on 56 pediatric medulloblastoma patients. Hazard ratios (HR) and 95% confidence intervals (CI) for the association between mdNLR and survival were evaluated using Cox proportional hazard models. Results: Compared to patients who were alive at last follow-up (n = 43), the mean mdNLR value was slightly higher in deceased patients (n = 13) (12.3 vs. 5.2,P = 0.163). Elevated log-transformed mdNLR was suggestively associated with an increased likelihood of death in unadjusted models (HR=1.43, 95%CI: 0.92–2.22) and significantly associated with mortality in adjusted models (HR=1.61, 95%CI: 1.01–2.58). Discussion: Future work is warranted to investigate the relationship between mdNLR outcomes in specific pediatric medulloblastoma molecular subgroups.

Original languageEnglish (US)
Pages (from-to)71-74
Number of pages4
JournalCancer Epidemiology
Volume59
DOIs
StatePublished - Apr 2019

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pilot study of DNA methylation-derived neutrophil-to-lymphocyte ratio and survival in pediatric medulloblastoma'. Together they form a unique fingerprint.

Cite this